Literature DB >> 6255544

Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis.

R Negroni, A M Robles, A Arechavala, M A Tuculet, R Galimberti.   

Abstract

Ketoconazole was given orally to 33 patients with paracoccidioidomycosis and 23 with histoplasmosis. There were 55 men and one woman, and ages ranged from 28 to 67 years. Each patient had either the chronic disseminated or the chronic pulmonary form of disease. The diagnosis was established in 54 patients by culture of Paracoccidioides brasiliensis or Histoplasma capsulatum from lesions and in two patients by the clinical picture and results of serologic tests for histoplasmosis. The initial dosage was 400 mg per day. The dosage was reduced to 200 mg when a cure was achieved. The duration of treatment ranged from two to 18 months. Results of treatment were classified as very good (clinical and serologic cure) in 23 (41%) of the patients; good (clinical cure only) in 28 (50%); fair (partial improvement) in one (2%); and poor (no improvement) in three (5%). The results were not assessable in one patient who did not complete therapy. The three patients who did not respond to treatment had less than or equal to 0.19 microgram of ketoconazole/ml in their blood. The drug was well tolerated, and no side effects were reported.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255544     DOI: 10.1093/clinids/2.4.643

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

Review 1.  Drugs for treating paracoccidioidomycosis.

Authors:  V M Menezes; B G O Soares; C J F Fontes
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Comparative efficacy of ketoconazole and mebendazole in experimental trichinosis.

Authors:  J A Hess; P H Chandrasekar; M Mortiere; J A Molinari
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  EPIDEMIOLOGY OF PARACOCCIDIOIDOMYCOSIS.

Authors:  Roberto Martinez
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

Review 4.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

6.  Therapy of fungal infections.

Authors:  D J Drutz
Journal:  Bull N Y Acad Med       Date:  1982-11

7.  Treatment of disseminated histoplasmosis in hamsters.

Authors:  J L Finquelievich; R Negroni; C Iovannitti; A J Bava
Journal:  Mycopathologia       Date:  1989-02       Impact factor: 2.574

8.  Ketoconazole in the treatment of experimental murine paracoccidioidomycosis.

Authors:  A K Ueda; M Franco; S A Fabio; F R Prestes
Journal:  Mycopathologia       Date:  1987-04       Impact factor: 2.574

9.  Paracoccidioidomycosis: a comparative study of the evolutionary serologic, clinical and radiologic results for patients treated with ketoconazole or amphotericin B plus sulfonamides.

Authors:  S A Marques; N L Dillon; M F Franco; M C Habermann; J C Lastoria; H O Stolf; J Marcondes; W Grizzo; N C Silva; M R Cavariani
Journal:  Mycopathologia       Date:  1985-01       Impact factor: 2.574

10.  Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela.

Authors:  Moritz Kayser; Volker Rickerts; Nora Drick; Jasmin Gerkrath; Hans Kreipe; Bisharah Soudah; Tobias Welte; Hendrik Suhling
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.